Cogent Biosciences (COGT) Current Leases (2019 - 2026)

Cogent Biosciences (COGT) has reported Current Leases for 8 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 14.15% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 14.15% YoY), while the FY2025 annual figure was $1.5 million, down 1.15% from the prior year.
• Current Leases fell to $1.4 million in Q1 2026 per COGT's latest filing, from $1.5 million in the prior quarter.
• Across five years, Current Leases topped out at $9.1 million in Q2 2022 and bottomed at $947000.0 in Q1 2023.
• Historically, Current Leases has averaged $2.0 million across 5 years, with a median of $1.5 million in 2024.
• Annual changes were most pronounced in 2022 — Current Leases surged 314.7% — and 2023, when it tumbled 87.0%.
• Cogent Biosciences' Current Leases stood at $1.4 million in 2022, then decreased by 2.6% to $1.4 million in 2023, then increased by 12.91% to $1.6 million in 2024, then retreated by 1.15% to $1.5 million in 2025, then declined by 10.6% to $1.4 million in 2026.
• Business Quant data shows COGT's Current Leases at $1.4 million in Q1 2026, $1.5 million in Q4 2025, and $1.7 million in Q3 2025.